Plain-English translation of NCT05427786 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This study is testing whether , a medication injected directly into the heart arteries before stent placement, can help prevent a serious complication called no-reflow—where blood flow in the artery slows down or stops during the procedure. Half of the participants will receive the medication before their stent surgery, and the other half will receive standard treatment without it. Researchers want to see if this medication can protect the heart and improve outcomes.
During heart stent procedures, sometimes the artery's blood flow unexpectedly decreases, which can damage the heart and complicate recovery. This trial is testing whether giving this medication beforehand can prevent that dangerous complication from happening.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will be randomly assigned to one of two groups. Both groups will undergo coronary stent placement surgery, but one group will receive the medication injected into the artery before the balloon therapy begins, while the other group will receive standard surgery without the pre-treatment medication. The study involves the procedure itself and clinical follow-up visits to monitor your recovery and heart function.
AI-generated summary from trial data · Jun 14, 2026 · Not medical advice
South Korea